| 1 | Recent trouble relaxing | Anxiety | UKBB00000745 | 55.87 |
| 2 | CD83/TREM2 ratio | GCST90313908 | 55.18 |
| 3 | CTSO/IGF2R ratio | GCST90314317 | 53.83 |
| 4 | MARCO levels | GCST90469861 | 53.13 |
| 5 | APCS levels | GCST90468328 | 52.81 |
| 6 | PTPRZ1 levels | GCST90470388 | 51.60 |
| 7 | TREM2 levels | GCST90470960 | 46.35 |
| 8 | ALCAM/LRRC25 ratio | GCST90313239 | 45.07 |
| 9 | FOLR2/THY1 ratio | GCST90314867 | 43.52 |
| 10 | Degree of unsaturation | GCST90502746 | 42.58 |
| 11 | T1 FreeSurfer DKT rh lateraloccipital area | GCST90384295 | 42.30 |
| 12 | CD300C/FOLR2 ratio | GCST90313787 | 42.01 |
| 13 | GLB1/PCSK9 ratio | GCST90314933 | 41.48 |
| 14 | CFI levels | GCST90468730 | 40.82 |
| 15 | FOLR3 levels | GCST90469261 | 40.16 |
| 16 | HAVCR2/TREM2 ratio | GCST90315031 | 40.07 |
| 17 | CD40LG/EREG ratio | GCST90313820 | 39.68 |
| 18 | CD300C/LRRC25 ratio | GCST90313790 | 39.59 |
| 19 | LRRC25 levels | GCST90469801 | 39.21 |
| 20 | HPCAL1/PMVK ratio | GCST90315076 | 38.85 |
| 21 | T1 FreeSurfer DK rh lateraloccipital area | GCST90385699 | 38.03 |
| 22 | FOLR2/HAVCR2 ratio | GCST90314865 | 37.30 |
| 23 | Phosphatidylcholine-O_32:1_[M+H]1+/Phosphatidylcholine-P_32:0_[M+H]1+/Phosphatidylethanolamine-O_35:1_[M+H]1+ levels | GCST90060254 | 37.28 |
| 24 | Lactosyl-N-nervonoyl-sphingosine (d18:1/24:1) levels | GCST90200098 | 37.11 |
| 25 | Monounsaturated fatty acid levels | GCST90502038 | 37.09 |
| 26 | MELTF levels | GCST90469885 | 37.05 |
| 27 | UFC1 levels | GCST90243245 | 36.27 |
| 28 | Recent feelings of tiredness or low energy | Depression | UKBB00000740 | 36.11 |
| 29 | PIK3IP1/TNFRSF1A ratio | GCST90315653 | 35.97 |
| 30 | IFIT2 levels | GCST90090864 | 35.95 |
| 31 | CALCOCO1/CASP3 ratio | GCST90313596 | 35.92 |
| 32 | EREG/MPIG6B ratio | GCST90314704 | 35.77 |
| 33 | CES2 levels | GCST90468719 | 35.62 |
| 34 | ADGRE2/B4GALT1 ratio | GCST90313174 | 35.31 |
| 35 | Type 2 diabetes | GCST90086072 | 35.00 |
| 36 | MMP12 levels | GCST90469916 | 34.49 |
| 37 | Cholesterol_[M+H-H2O]1+ levels | GCST90060133 | 34.18 |
| 38 | CDCP1 levels | GCST90468667 | 34.11 |
| 39 | ITGA5 levels | GCST90469635 | 33.68 |
| 40 | Free cholesterol in very large HDL | GCST90500383 | 33.19 |
| 41 | MRC1 levels | GCST90469939 | 33.18 |
| 42 | ADA2/COMP ratio | GCST90313166 | 33.16 |
| 43 | Triacylglycerol_58:7_[M+NH4]1+ levels | GCST90060564 | 32.89 |
| 44 | CASP3/LYN ratio | GCST90313635 | 32.85 |
| 45 | HGF/MMP8 ratio | GCST90315055 | 32.69 |
| 46 | Phospholipids in large LDL | GCST90498049 | 32.50 |
| 47 | Total fatty acid levels | GCST90502220 | 32.32 |
| 48 | LRG1 levels | GCST90469793 | 32.28 |
| 49 | Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093045 | 32.16 |
| 50 | PSRC1/SORT1 ratio | GCST90315742 | 32.04 |
| 51 | Recent inability to stop or control worrying | Anxiety | UKBB00000742 | 31.58 |
| 52 | GAS6/NOTCH1 ratio | GCST90314918 | 31.58 |
| 53 | MFGE8 levels | GCST90469900 | 31.56 |
| 54 | CD59/SCARB2 ratio | GCST90313859 | 31.43 |
| 55 | LTBP2/PDGFRA ratio | GCST90315338 | 31.40 |
| 56 | PLAUR/TREM2 ratio | GCST90315676 | 30.72 |
| 57 | SERPIND1 levels | GCST90470595 | 30.57 |
| 58 | GAS6 levels | GCST90469305 | 30.42 |
| 59 | C1QA levels | GCST90468485 | 30.39 |
| 60 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90501075 | 30.35 |
| 61 | Phospholipids in very large HDL | GCST90500451 | 30.04 |
| 62 | CPB2 levels | GCST90468840 | 30.03 |
| 63 | Monounsaturated fatty acid levels | GCST90502362 | 30.00 |
| 64 | CHIT1 levels | GCST90468744 | 29.83 |
| 65 | APOA2 levels | GCST90468332 | 29.69 |
| 66 | ADGRE2/IFNGR1 ratio | GCST90313177 | 29.57 |
| 67 | SERPING1 levels | GCST90470600 | 29.36 |
| 68 | Plasma 4-guanidinobutanoate levels in chronic kidney disease | GCST90264620 | 29.32 |
| 69 | CRHBP/TREM2 ratio | GCST90314260 | 29.22 |
| 70 | CD83 levels | GCST90468652 | 29.07 |
| 71 | ITIH3/VCAM1 ratio | GCST90315236 | 29.02 |
| 72 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500506 | 29.02 |
| 73 | ITGB5/S100A4 ratio | GCST90315233 | 28.99 |
| 74 | Phospholipids to Total Lipids in Large HDL percentage | GCST90497868 | 28.87 |
| 75 | Total fatty acid levels | GCST90502727 | 28.84 |
| 76 | PRCP levels | GCST90470314 | 28.78 |
| 77 | ADA2/VCAM1 ratio | GCST90313167 | 28.73 |
| 78 | PIK3IP1/TNFRSF1B ratio | GCST90315654 | 28.66 |
| 79 | CD300E/LILRA5 ratio | GCST90313798 | 28.59 |
| 80 | T1 FreeSurfer BA lh BA3a exvivo thickness | GCST90385521 | 28.54 |
| 81 | ERBB3 levels | GCST90469140 | 28.28 |
| 82 | FABP4/SNCG ratio | GCST90314759 | 28.03 |
| 83 | Total Lipids in HDL | GCST90497401 | 27.97 |
| 84 | MANF/NCK2 ratio | GCST90315359 | 27.92 |
| 85 | CD300C/HAVCR2 ratio | GCST90313789 | 27.69 |
| 86 | Average diameter for HDL particles | GCST90497446 | 27.62 |
| 87 | Triacylglycerol (52:4) [NL-16:0] levels | GCST90025170 | 27.59 |
| 88 | Triglycerides x anxiety interaction (2df test) | GCST90570677 | 27.51 |
| 89 | HMOX1 levels | GCST90469465 | 27.17 |
| 90 | PLG levels | GCST90470257 | 27.14 |
| 91 | SIGLEC5 levels | GCST90470633 | 27.07 |
| 92 | IDP dMRI ProbtrackX ISOVF atr l | GCST90004527 | 27.06 |
| 93 | CPVL levels | GCST90468848 | 27.04 |
| 94 | GFRA2 levels | GCST90469329 | 27.03 |
| 95 | CTSL levels | GCST90468914 | 26.92 |
| 96 | NPY/SMOC1 ratio | GCST90315551 | 26.85 |
| 97 | DAPK2 levels | GCST90468945 | 26.83 |
| 98 | Cholesterol to Total Lipids in Small HDL percentage | GCST90499369 | 26.81 |
| 99 | CDCP1/MSR1 ratio | GCST90313938 | 26.80 |
| 100 | PAPPA levels | GCST90470157 | 26.78 |
| 101 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498583 | 26.69 |
| 102 | LILRB2 levels | GCST90469777 | 26.63 |
| 103 | MPHOSPH8/PSRC1 ratio | GCST90315478 | 26.51 |
| 104 | Cholesteryl Esters to Total Lipids in Small HDL percentage | GCST90499403 | 26.49 |
| 105 | Cholesteryl esters in small HDL (UKB data field 23576) | GCST90269673 | 26.46 |
| 106 | CD83/HAVCR2 ratio | GCST90313904 | 26.40 |
| 107 | CLEC4A levels | GCST90468771 | 26.33 |
| 108 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90501068 | 26.30 |
| 109 | Free cholesterol in small HDL (UKB data field 23577) | GCST90269674 | 26.01 |
| 110 | TIMD4 levels | GCST90470866 | 25.97 |
| 111 | Free Cholesterol in HDL | GCST90497379 | 25.76 |
| 112 | TEK levels | GCST90470829 | 25.70 |
| 113 | FOLR2/MSR1 ratio | GCST90314866 | 25.67 |
| 114 | CTSL levels | GCST90012073 | 25.67 |
| 115 | KLK7 levels | GCST90469706 | 25.62 |
| 116 | CTSO levels | GCST90468915 | 25.43 |
| 117 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90132630 | 25.29 |
| 118 | Triglyceride levels in very large HDL | GCST90132636 | 25.26 |
| 119 | Ulcerative colitis (strict) with PSC | FING00001389 | 25.21 |
| 120 | SIGLEC10 levels | GCST90470630 | 25.19 |
| 121 | Phospholipids in HDL | GCST90497430 | 25.19 |
| 122 | Cholesterol in small HDL (UKB data field 23575) | GCST90269672 | 25.10 |
| 123 | Omega-3 fatty acids to total fatty acids percentage | GCST90502087 | 25.10 |
| 124 | CD300LG/TNFRSF1A ratio | GCST90313803 | 25.01 |
| 125 | Total lipids in large HDL | GCST90497818 | 24.98 |
| 126 | Recent worrying too much about different things | Anxiety | UKBB00000746 | 24.93 |
| 127 | Average diameter for VLDL particles | GCST90093002 | 24.92 |
| 128 | Cholesteryl ester levels in small HDL | GCST90092946 | 24.88 |
| 129 | Total concentration of lipoprotein particles (UKB data field 23427) | GCST90269524 | 24.76 |
| 130 | APOA1 levels | GCST90497119 | 24.74 |
| 131 | CD300C/NBL1 ratio | GCST90313792 | 24.74 |
| 132 | MMP9/PLTP ratio | GCST90315471 | 24.72 |
| 133 | aparc-a2009s rh volume G+S-subcentral | GCST90003002 | 24.64 |
| 134 | ADGRE1 levels | GCST90468236 | 24.61 |
| 135 | FIS1/HSPA1A ratio | GCST90314825 | 24.58 |
| 136 | Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093049 | 24.57 |
| 137 | Free cholesterol in small HDL | GCST90499425 | 24.54 |
| 138 | Average diameter for VLDL particles (UKB data field 23431) | GCST90269528 | 24.50 |
| 139 | CD164/LGMN ratio | GCST90313741 | 24.44 |
| 140 | AXL/CD163 ratio | GCST90313418 | 24.44 |
| 141 | CTSD levels | GCST90468910 | 24.39 |
| 142 | Concentration of large HDL particles | GCST90497836 | 24.34 |
| 143 | CD99/RELT ratio | GCST90313930 | 24.29 |
| 144 | LRIG1 levels | GCST90469794 | 24.25 |
| 145 | Concentration of small HDL particles | GCST90499461 | 24.23 |
| 146 | Total cholines levels | GCST90497183 | 24.21 |
| 147 | GBA1 levels | GCST90423262 | 24.19 |
| 148 | Free cholesterol in HDL (UKB data field 23422) | GCST90269519 | 24.18 |
| 149 | PDGFB/PTPN6 ratio | GCST90315625 | 24.12 |
| 150 | Urine 16a-hydroxy DHEA 3-sulfate levels in chronic kidney disease | GCST90264329 | 24.10 |
| 151 | Concentration of HDL particles (UKB data field 23430) | GCST90269527 | 24.05 |
| 152 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90500965 | 24.02 |
| 153 | X-13671 levels | GCST90243829 | 23.97 |
| 154 | Other bacterial diseases | FING00000968 | 23.93 |
| 155 | Average diameter for LDL particles | GCST90498458 | 23.78 |
| 156 | CALCOCO1/VPS53 ratio | GCST90313612 | 23.75 |
| 157 | Free cholesterol levels in HDL | GCST90092824 | 23.66 |
| 158 | AXL/MSR1 ratio | GCST90313422 | 23.55 |
| 159 | Concentration of HDL particles | GCST90497414 | 23.54 |
| 160 | FURIN levels | GCST90469277 | 23.50 |
| 161 | ATP5IF1/FIS1 ratio | GCST90313385 | 23.42 |
| 162 | FOLR2 levels | GCST90469260 | 23.40 |
| 163 | Triglyceride levels in large HDL | GCST90092854 | 23.39 |
| 164 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90499302 | 23.14 |
| 165 | HDL cholesterol | GCST002223 | 23.13 |
| 166 | LTB4R levels | GCST90422164 | 23.11 |
| 167 | Triglyceride levels in very large HDL | GCST90093014 | 23.09 |
| 168 | Total concentration of lipoprotein particles | GCST90500101 | 23.09 |
| 169 | F9 levels | GCST90469172 | 23.06 |
| 170 | Cholesterol levels in chylomicrons and extremely large VLDL | GCST90500905 | 22.95 |
| 171 | DNAJA2/PRDX5 ratio | GCST90314506 | 22.91 |
| 172 | FAS levels | GCST90090701 | 22.87 |
| 173 | Free cholesterol to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23582) | GCST90269679 | 22.84 |
| 174 | ALB levels | GCST90475106 | 22.76 |
| 175 | Phospholipids to Total Lipids in Very Large HDL percentage | GCST90500472 | 22.71 |
| 176 | CD163/MSR1 ratio | GCST90313738 | 22.69 |
| 177 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90500975 | 22.67 |
| 178 | Sleep duration | GCST003839 | 22.63 |
| 179 | Saturated fatty acids levels | GCST90502675 | 22.60 |
| 180 | HDL cholesterol levels | GCST90497340 | 22.58 |
| 181 | MANSC4 levels | GCST90469848 | 22.55 |
| 182 | MMP9/OLR1 ratio | GCST90315467 | 22.55 |
| 183 | Phosphatidylcholine-O_44:5_[M+OAc]1-/Phosphatidylcholine-P_44:4_[M+OAc]1- levels | GCST90060557 | 22.54 |
| 184 | Radial styloid tenosynovitis [de Quervain] | FING00001237 | 22.54 |
| 185 | PLA2G7 levels | GCST90470249 | 22.52 |
| 186 | Total lipids in HDL (UKB data field 23426) | GCST90269523 | 22.47 |
| 187 | CD300E/CD59 ratio | GCST90313794 | 22.47 |
| 188 | Phosphoglycerides levels | GCST90499265 | 22.44 |
| 189 | Triglycerides to Total Lipids in Medium LDL percentage | GCST90498885 | 22.39 |
| 190 | Haematocrit percentage (UKB data field 30030) | GCST90468073 | 22.25 |
| 191 | Linoleic acid to total fatty acids percentage | GCST90498321 | 22.23 |
| 192 | ITGA5/VCAM1 ratio | GCST90315206 | 22.17 |
| 193 | Parkinson's disease or first degree relation to individual with Parkinson's disease | GCST009325 | 22.15 |
| 194 | Free cholesterol in medium HDL (UKB data field 23570) | GCST90269667 | 22.14 |
| 195 | CLUL1 levels | GCST90468792 | 22.10 |
| 196 | BTN2A1/CSF1 ratio | GCST90313541 | 22.10 |
| 197 | BTN2A1/SIGLEC1 ratio | GCST90313548 | 22.09 |
| 198 | CD33 levels | GCST90468625 | 22.05 |
| 199 | ALCAM levels | GCST90468279 | 22.01 |
| 200 | Hands-free device/speakerphone use with mobile phone in last 3 month | Electronic device use | UKBB00000304 | 21.95 |
| 201 | IGF2R/RNASET2 ratio | GCST90315132 | 21.92 |
| 202 | Docosahexaenoic acid levels | GCST90497256 | 21.91 |
| 203 | Heart rate variability (corrected standard deviation of normal-to-normal intervals) | GCST90281266 | 21.88 |
| 204 | Triglycerides | GCST002216 | 21.85 |
| 205 | Concentration of small HDL particles (UKB data field 23572) | GCST90269669 | 21.83 |
| 206 | Polyunsaturated fatty acid levels | GCST90502606 | 21.81 |
| 207 | Linoleic acid levels | GCST90502294 | 21.80 |
| 208 | APCS levels | GCST90428463 | 21.80 |
| 209 | Phosphatidylcholine levels | GCST90499248 | 21.80 |
| 210 | Concentration of medium HDL particles | GCST90498617 | 21.76 |
| 211 | MARCO/SIGLEC1 ratio | GCST90315387 | 21.75 |
| 212 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502074 | 21.74 |
| 213 | GALNT7 levels | GCST90469299 | 21.66 |
| 214 | HDL cholesterol | GCST90018736 | 21.51 |
| 215 | Triglycerides in large VLDL (UKB data field 23501) | GCST90269598 | 21.44 |
| 216 | Triglyceride levels in large VLDL | GCST90092878 | 21.42 |
| 217 | CCL27 levels | GCST90468579 | 21.38 |
| 218 | Free cholesterol levels in small HDL | GCST90092948 | 21.38 |
| 219 | PMVK/PRDX5 ratio | GCST90315694 | 21.37 |
| 220 | Monounsaturated fatty acid levels | GCST90502363 | 21.35 |
| 221 | Phospholipids in large VLDL | GCST90498247 | 21.30 |
| 222 | ARTN levels | GCST90468372 | 21.29 |
| 223 | Phosphatidylcholines levels (UKB data field 23437) | GCST90269534 | 21.28 |
| 224 | Average diameter for VLDL particles | GCST90500290 | 21.18 |
| 225 | Linoleic acid levels | GCST90092880 | 21.14 |
| 226 | HDL cholesterol | Blood biochemistry | UKBB00000306 | 21.11 |
| 227 | Total esterified cholesterol levels | GCST90500036 | 21.07 |
| 228 | Concentration of large HDL particles | GCST90092851 | 21.06 |
| 229 | Phospholipids in small LDL | GCST90499673 | 21.06 |
| 230 | Clonal hematopoiesis (large clone) | GCST90102621 | 21.04 |
| 231 | Cholesterol to Total Lipids in Medium HDL percentage | GCST90498519 | 21.03 |
| 232 | Average diameter for HDL particles | GCST90092828 | 21.02 |
| 233 | Free Cholesterol to Total Lipids in Small HDL percentage | GCST90499431 | 20.97 |
| 234 | AXL levels | GCST90468406 | 20.96 |
| 235 | Total lipids in large HDL (UKB data field 23559) | GCST90269656 | 20.95 |
| 236 | PECAM1/SOD2 ratio | GCST90315647 | 20.91 |
| 237 | Urine andro steroid monosulfate C19H28O6S (1)* levels in chronic kidney disease | GCST90264796 | 20.83 |
| 238 | Diacylglycerol_36:2_[M+H-H2O]1+ levels | GCST90060191 | 20.83 |
| 239 | Phospholipid levels in very large HDL | GCST90132642 | 20.82 |
| 240 | DNAJA2/FIS1 ratio | GCST90314501 | 20.81 |
| 241 | PLTP levels | GCST90470262 | 20.78 |
| 242 | Free cholesterol levels in very large HDL | GCST90132680 | 20.75 |
| 243 | Free Cholesterol in HDL | GCST90497381 | 20.74 |
| 244 | APOA1 levels | GCST90269537 | 20.70 |
| 245 | Cholesteryl esters to total lipids ratio in large LDL | GCST90092859 | 20.69 |
| 246 | Concentration of large HDL particles (UKB data field 23558) | GCST90269655 | 20.69 |
| 247 | Free cholesterol levels in very large HDL | GCST90093008 | 20.59 |
| 248 | Phospholipid levels in very large HDL | GCST90093012 | 20.57 |
| 249 | Triglycerides x depression interaction (2df test) | GCST90570679 | 20.54 |
| 250 | Free cholesterol in medium HDL | GCST90498563 | 20.52 |
| 251 | Linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1] levels | GCST90200103 | 20.50 |
| 252 | ADGRE5/NOTCH1 ratio | GCST90313181 | 20.47 |
| 253 | Liver condition (ex. cirrhosis) | GCST90475270 | 20.47 |
| 254 | Total concentration of lipoprotein particles | GCST90092990 | 20.46 |
| 255 | Osteoporosis, osteopenia and pathological fracture | musculoskeletal | UKBB00000600 | 20.45 |
| 256 | Total lipids in very large HDL | GCST90500423 | 20.41 |
| 257 | SIGLEC8 levels | GCST90089886 | 20.40 |
| 258 | SCARB2 levels | GCST90470535 | 20.40 |
| 259 | CTSC levels | GCST90468909 | 20.39 |
| 260 | ADGRE5/VCAM1 ratio | GCST90313184 | 20.39 |
| 261 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502155 | 20.38 |
| 262 | CCL17/F2R ratio | GCST90313686 | 20.32 |
| 263 | Average diameter for VLDL particles | GCST90500279 | 20.30 |
| 264 | Cholesterol levels in small HDL | GCST90092944 | 20.23 |
| 265 | EGFLAM levels | GCST90421651 | 20.16 |
| 266 | GSTA1/PBLD ratio | GCST90314994 | 20.15 |
| 267 | Triglyceride levels | GCST90239663 | 20.15 |
| 268 | CD69/SNAP29 ratio | GCST90313887 | 20.13 |
| 269 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497790 | 20.13 |
| 270 | Free cholesterol in large HDL | GCST90497786 | 20.13 |
| 271 | 1-stearoyl-gpc (18:0) levels | GCST90199732 | 20.12 |
| 272 | Triglycerides to Total Lipids in Large HDL percentage | GCST90497896 | 20.03 |
| 273 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502051 | 19.97 |
| 274 | Free cholesterol to total lipids ratio in large HDL | GCST90092849 | 19.96 |
| 275 | Positional arithmetic | Fluid intelligence / reasoning | UKBB00000654 | 19.95 |
| 276 | Phospholipids in HDL (UKB data field 23414) | GCST90269511 | 19.89 |
| 277 | Triacylglycerol_56:7_[M+NH4]1+ levels | GCST90060551 | 19.87 |
| 278 | Concentration of very large HDL particles | GCST90500431 | 19.84 |
| 279 | Free cholesterol levels in large HDL | GCST90092848 | 19.84 |
| 280 | Hyperlipidemia | GCST90090994 | 19.83 |
| 281 | ADH4/DCXR ratio | GCST90313190 | 19.81 |
| 282 | HDL cholesterol levels (UKB data field 23406) | GCST90269503 | 19.81 |
| 283 | Monounsaturated fatty acid levels | GCST90502346 | 19.79 |
| 284 | Phosphatidylcholine levels | GCST90092937 | 19.76 |
| 285 | Concentration of small HDL particles | GCST90092951 | 19.76 |
| 286 | Total lipid levels in HDL | GCST90092825 | 19.75 |
| 287 | Average diameter for HDL particles (UKB data field 23433) | GCST90269530 | 19.75 |
| 288 | Free cholesterol in medium VLDL | GCST90498965 | 19.73 |
| 289 | Phospholipids to total lipids ratio in large LDL | GCST90092865 | 19.72 |
| 290 | T1 FreeSurfer a2009s lh S central thickness | GCST90384786 | 19.71 |
| 291 | Cholesterol in Medium LDL | GCST90498703 | 19.70 |
| 292 | Docosahexaenoic acid to total fatty acids percentage | GCST90501997 | 19.69 |
| 293 | Social trust (aggregated) | GCST90319315 | 19.66 |
| 294 | Total lipid levels in large HDL | GCST90092850 | 19.66 |
| 295 | Concentration of HDL particles | GCST90092826 | 19.65 |
| 296 | Linoleic acid levels | GCST90502004 | 19.64 |
| 297 | LDLR levels | GCST90469750 | 19.64 |
| 298 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 19.63 |
| 299 | Phospholipids in large HDL (UKB data field 23560) | GCST90269657 | 19.59 |
| 300 | Phosphoglycerides levels (UKB data field 23434) | GCST90269531 | 19.59 |
| 301 | ATF6 levels | GCST90617260 | 19.57 |
| 302 | Total lipid levels in lipoprotein particles | GCST90500085 | 19.53 |
| 303 | FAM20A levels | GCST90469185 | 19.53 |
| 304 | Phospholipid levels in large HDL | GCST90092852 | 19.51 |
| 305 | Concentration of very large HDL particles | GCST90093011 | 19.50 |
| 306 | CD163 levels | GCST90468600 | 19.46 |
| 307 | Chronic bronchitis | respiratory | UKBB00000136 | 19.46 |
| 308 | Total cholesterol levels | GCST90500015 | 19.44 |
| 309 | MERTK levels | GCST90469890 | 19.44 |
| 310 | APOA levels | GCST90468061 | 19.44 |
| 311 | Free cholesterol in very large VLDL | GCST90500581 | 19.37 |
| 312 | MSRA/SNAP29 ratio | GCST90315500 | 19.36 |
| 313 | Parental longevity (both parents in top 10%) | GCST006698 | 19.34 |
| 314 | Cholesteryl Esters to Total Lipids in Medium HDL percentage | GCST90498550 | 19.33 |
| 315 | LRP1 levels | GCST90469797 | 19.32 |
| 316 | Cholesteryl Esters in Large VLDL | GCST90498146 | 19.31 |
| 317 | ACY1/GSTA1 ratio | GCST90313163 | 19.31 |
| 318 | NRP2 levels | GCST90470086 | 19.27 |
| 319 | Free cholesterol in very large VLDL | GCST90500575 | 19.26 |
| 320 | Total cholines levels (UKB data field 23436) | GCST90269533 | 19.26 |
| 321 | IGF2R levels | GCST90469526 | 19.26 |
| 322 | Triacylglycerol_56:6_[M+NH4]1+ levels | GCST90060553 | 19.25 |
| 323 | Cholesterol in Large LDL | GCST90497919 | 19.24 |
| 324 | SOD2 levels | GCST90470705 | 19.23 |
| 325 | LILRA2 levels | GCST90469771 | 19.22 |
| 326 | Total fatty acid levels | GCST90502726 | 19.11 |
| 327 | Cholesteryl Esters in HDL | GCST90497357 | 19.11 |
| 328 | Sleep disorders | neurological | UKBB00000776 | 19.11 |
| 329 | LAT2/MANF ratio | GCST90315277 | 19.10 |
| 330 | Phospholipids in medium VLDL | GCST90499024 | 19.04 |
| 331 | GPNMB levels | GCST90469393 | 19.04 |
| 332 | Concentration of HDL particles | GCST90497406 | 19.03 |
| 333 | High density lipoprotein cholesterol levels | GCST90278635 | 19.01 |
| 334 | Metabolic syndrome | GCST90444489 | 18.98 |
| 335 | ITGB1 levels | GCST90469643 | 18.95 |
| 336 | Free cholesterol to total lipids ratio in very large HDL | GCST90093009 | 18.89 |
| 337 | Lysophosphatidylcholine_16:1_[M+H]1+/Lysophosphatidylethanolamine_19:1_[M+H]1+ levels | GCST90060148 | 18.88 |
| 338 | Cholesteryl Esters in Large LDL | GCST90497949 | 18.87 |
| 339 | T1 FreeSurfer a2009s lh G precentral volume | GCST90384844 | 18.86 |
| 340 | CD1C levels | GCST90468604 | 18.86 |
| 341 | Phospholipids in medium LDL | GCST90498831 | 18.85 |
| 342 | Phosphoglycerides levels | GCST90092938 | 18.82 |
| 343 | VCAM1 levels | GCST90471031 | 18.82 |
| 344 | AXIN1/CALCOCO1 ratio | GCST90313402 | 18.79 |
| 345 | NRCAM/NTRK2 ratio | GCST90315552 | 18.78 |
| 346 | Average diameter for LDL particles | GCST90498457 | 18.76 |
| 347 | NPTX2 levels | GCST90470079 | 18.75 |
| 348 | Total lipid levels in very large HDL | GCST90093010 | 18.74 |
| 349 | Total cholines levels | GCST90092812 | 18.73 |
| 350 | CD163/MARCO ratio | GCST90313737 | 18.72 |
| 351 | Free cholesterol in medium HDL | GCST90498562 | 18.70 |
| 352 | Omega-3 fatty acid levels | GCST90502062 | 18.70 |
| 353 | Polyunsaturated fatty acid levels | GCST90502618 | 18.70 |
| 354 | Omega-3 fatty acid levels | GCST90502056 | 18.69 |
| 355 | Free cholesterol in large HDL (UKB data field 23563) | GCST90269660 | 18.61 |
| 356 | wg rh intensity-contrast parahippocampal | GCST90003842 | 18.59 |
| 357 | Phospholipids to total lipids in IDL percentage (UKB data field 23609) | GCST90269706 | 18.58 |
| 358 | RRM2 levels | GCST90470501 | 18.58 |
| 359 | CD300A levels | GCST90468619 | 18.58 |
| 360 | Hard cheese liking | GCST90094778 | 18.55 |
| 361 | C2/LILRB4 ratio | GCST90313554 | 18.51 |
| 362 | Triacylglycerol_56:5_[M+NH4]1+ levels | GCST90060554 | 18.48 |
| 363 | Linoleic acid levels | GCST90502306 | 18.46 |
| 364 | Cholesterol levels in very large HDL | GCST90093004 | 18.46 |
| 365 | Triglyceride levels in medium VLDL | GCST90092926 | 18.46 |
| 366 | CCN2/TPP1 ratio | GCST90313718 | 18.45 |
| 367 | METAP2/RILP ratio | GCST90315433 | 18.42 |
| 368 | Neuroticism | GCST002920 | 18.41 |
| 369 | Triglyceride to HDL cholesterol ratio | GCST90295950 | 18.40 |
| 370 | Cerebrospinal fluid unidentified metabolite levels (HILIC Metabolomics ID: 3.04_132.06) | GCST90291582 | 18.39 |
| 371 | Blood cell traits latent factor 7 (white cell) | GCST90559249 | 18.37 |
| 372 | Total phospholipid levels in lipoprotein particles | GCST90500124 | 18.34 |
| 373 | ITGA2 levels | GCST90469634 | 18.32 |
| 374 | APOD levels | GCST90468337 | 18.30 |
| 375 | Docosahexaenoic acid to total fatty acids percentage | GCST90502281 | 18.29 |
| 376 | Sleep disorders | Episodic and paroxysmal disorders | UKBB00000775 | 18.26 |
| 377 | MAD1L1/POLR2F ratio | GCST90315354 | 18.26 |
| 378 | Degree of unsaturation | GCST90502230 | 18.24 |
| 379 | Cholesterol to Total Lipids in Large HDL percentage | GCST90497732 | 18.24 |
| 380 | Concentration of large HDL particles | GCST90497828 | 18.24 |
| 381 | Glycosyl ceramide (d18:2/24:1, d18:1/24:2) levels | GCST90200118 | 18.22 |
| 382 | Fruit juice liking | GCST90094768 | 18.21 |
| 383 | NCS1 levels | GCST90470011 | 18.17 |
| 384 | Cholesterol in large HDL (UKB data field 23561) | GCST90269658 | 18.17 |
| 385 | Total fatty acid levels | GCST90502710 | 18.14 |
| 386 | PSAP levels | GCST90470351 | 18.13 |
| 387 | THPO levels | GCST90470857 | 18.13 |
| 388 | Saturated fatty acids levels | GCST90502658 | 18.11 |
| 389 | APOA levels | UKBB00000040 | 18.01 |
| 390 | MSR1 levels | GCST90469950 | 17.96 |
| 391 | Sphingomyelins levels | GCST90499983 | 17.94 |
| 392 | Total lipid levels in large VLDL | GCST90092874 | 17.93 |
| 393 | Triglycerides to Total Lipids in Medium LDL percentage | GCST90498881 | 17.92 |
| 394 | KAZALD1 levels | GCST90469665 | 17.92 |
| 395 | FN1 levels | GCST90469255 | 17.92 |
| 396 | Total lipids in large HDL | GCST90497815 | 17.91 |
| 397 | Linoleic acid levels (UKB data field 23449) | GCST90269546 | 17.89 |
| 398 | SUSD1/THPO ratio | GCST90315899 | 17.88 |
| 399 | NRCAM levels | GCST90470082 | 17.88 |
| 400 | Omega-6 fatty acids to total fatty acids percentage | GCST90499210 | 17.80 |
| 401 | Total lipids in very small VLDL | GCST90500813 | 17.79 |
| 402 | Concentration of large VLDL particles | GCST90092875 | 17.79 |
| 403 | ARHGEF12/DECR1 ratio | GCST90313349 | 17.79 |
| 404 | IDP dMRI TBSS L1 Cingulum cingulate gyrus R | GCST90004109 | 17.76 |
| 405 | Concentration of very large HDL particles | GCST90500436 | 17.76 |
| 406 | CD5/IL16 ratio | GCST90313861 | 17.75 |
| 407 | Cholesterol levels in large HDL | GCST90092844 | 17.71 |
| 408 | Total lipids in small HDL (UKB data field 23573) | GCST90269670 | 17.69 |
| 409 | Plasma 1-arachidonoyl-GPE (20:4n6)* levels in chronic kidney disease | GCST90264207 | 17.68 |
| 410 | MXRA8 levels | GCST90469968 | 17.68 |
| 411 | Cholesteryl Esters to Total Lipids in Very Large HDL percentage | GCST90500373 | 17.67 |
| 412 | B4GAT1 levels | GCST90468413 | 17.67 |
| 413 | AGR3 levels | GCST90468254 | 17.67 |
| 414 | 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) levels | GCST90199649 | 17.63 |
| 415 | CRADD/DARS1 ratio | GCST90314234 | 17.61 |
| 416 | Free cholesterol levels in medium HDL | GCST90092896 | 17.60 |
| 417 | Cholesteryl ester levels in very large HDL | GCST90093006 | 17.59 |
| 418 | Monounsaturated fatty acid levels | GCST90502358 | 17.59 |
| 419 | Dermatophytosis of nail (PheCode 110.11) | GCST90475562 | 17.59 |
| 420 | Average diameter for HDL particles | GCST90132702 | 17.57 |
| 421 | COMP/ITGAV ratio | GCST90314190 | 17.56 |
| 422 | Free Cholesterol to Total Lipids in Large HDL percentage | GCST90497793 | 17.55 |
| 423 | Cholesteryl Esters to Total Lipids in Large HDL percentage | GCST90497768 | 17.53 |
| 424 | Total concentration of lipoprotein particles | GCST90500103 | 17.52 |
| 425 | Free Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500791 | 17.48 |
| 426 | APOA1 levels | GCST90092808 | 17.47 |
| 427 | OLR1/OSM ratio | GCST90315583 | 17.46 |
| 428 | ROBO1 levels | GCST90470489 | 17.43 |
| 429 | Triglycerides in medium VLDL | GCST90499065 | 17.39 |
| 430 | Total lipids in medium HDL | GCST90498597 | 17.37 |
| 431 | SIGLEC1 levels | GCST90470632 | 17.37 |
| 432 | Triglycerides | GCST000758 | 17.32 |
| 433 | Phospholipids to Total Lipids in Large HDL percentage | GCST90497863 | 17.31 |
| 434 | Free Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500397 | 17.30 |
| 435 | MEGF9 levels | GCST90469884 | 17.27 |
| 436 | High density lipoprotein cholesterol levels | GCST90239651 | 17.27 |
| 437 | CLPP levels | GCST90468785 | 17.25 |
| 438 | Saturated fatty acids levels | GCST90502194 | 17.22 |
| 439 | Cholesteryl esters in HDL (UKB data field 23418) | GCST90269515 | 17.20 |
| 440 | Triglycerides in medium VLDL (UKB data field 23508) | GCST90269605 | 17.19 |
| 441 | Free Cholesterol to Total Lipids in Medium HDL percentage | GCST90498580 | 17.18 |
| 442 | ADGRE2/CD58 ratio | GCST90313175 | 17.18 |
| 443 | HEG1 levels | GCST90469444 | 17.18 |
| 444 | MAN1A2 levels | GCST90469843 | 17.17 |
| 445 | IGF2R/LGMN ratio | GCST90315131 | 17.15 |
| 446 | Glycoprotein acetyls levels | GCST90497320 | 17.15 |
| 447 | APOM levels | GCST90468342 | 17.14 |
| 448 | Cholesteryl Esters in Small LDL | GCST90499586 | 17.13 |
| 449 | Sleep apnea | neurological | UKBB00000774 | 17.12 |
| 450 | Cholesteryl esters in large HDL (UKB data field 23562) | GCST90269659 | 17.08 |
| 451 | Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500333 | 17.06 |
| 452 | CD164/CD99 ratio | GCST90313740 | 17.06 |
| 453 | Triglycerides in large LDL | GCST90498083 | 17.06 |
| 454 | C36:4 Phosphatidylethanolamine levels in chronic kidney disease | GCST90257357 | 17.02 |
| 455 | Cholesteryl ester levels in large HDL | GCST90092846 | 16.99 |
| 456 | NUDT5/RWDD1 ratio | GCST90315580 | 16.98 |
| 457 | Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632) | GCST90269729 | 16.97 |
| 458 | Plasma methylsuccinoylcarnitine levels in chronic kidney disease | GCST90265508 | 16.97 |
| 459 | Job involves shift work | Employment | UKBB00000385 | 16.97 |
| 460 | APOA1 levels | GCST90497122 | 16.95 |
| 461 | CPM/PCSK9 ratio | GCST90314216 | 16.95 |
| 462 | Phospholipids to total lipids ratio in large HDL | GCST90092853 | 16.94 |
| 463 | Triglycerides to Total Lipids in Large VLDL percentage | GCST90498287 | 16.90 |
| 464 | Cholesterol in Medium VLDL | GCST90498903 | 16.89 |
| 465 | Omega-3 fatty acid levels | GCST90502437 | 16.87 |
| 466 | Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500716 | 16.87 |
| 467 | Triglycerides to Total Lipids in Large VLDL percentage | GCST90498293 | 16.85 |
| 468 | Omega-3 fatty acid levels | GCST90502061 | 16.84 |
| 469 | ALB levels | GCST90025992 | 16.79 |
| 470 | Triglyceride levels in small VLDL | GCST90092978 | 16.77 |
| 471 | Triglycerides in very large VLDL | GCST90500671 | 16.75 |
| 472 | LILRA5 levels | GCST90469774 | 16.74 |
| 473 | HDL cholesterol | GCST000755 | 16.73 |
| 474 | Triglycerides in LDL | GCST90498469 | 16.73 |
| 475 | Triacylglycerol (54:2) [NL-18:0] levels | GCST90025175 | 16.73 |
| 476 | Triglycerides in large VLDL | GCST90498267 | 16.71 |
| 477 | Phospholipids in medium LDL | GCST90498832 | 16.71 |
| 478 | Phospholipids to Total Lipids in Very Small VLDL percentage | GCST90500866 | 16.71 |
| 479 | Phospholipid levels in HDL | GCST90092827 | 16.70 |
| 480 | Diacylglycerol_36:1_[M+H-H2O]1+ levels | GCST90060193 | 16.63 |
| 481 | CC2D1A/CRADD ratio | GCST90313663 | 16.62 |
| 482 | Free cholesterol to total lipids in medium HDL percentage (UKB data field 23642) | GCST90269739 | 16.62 |
| 483 | ITIH3 levels | GCST90469650 | 16.61 |
| 484 | ADGRE5/GAS6 ratio | GCST90313179 | 16.60 |
| 485 | Saturated fatty acids to total fatty acids percentage | GCST90499966 | 16.59 |
| 486 | Neuroendocrine tumor and carcinoma of stomach, excluding all cancers (controls excluding all cancers) | FING00000866 | 16.56 |
| 487 | Total Lipids in HDL | GCST90497393 | 16.55 |
| 488 | Cholesterol to Total Lipids in Medium LDL percentage | GCST90498714 | 16.54 |
| 489 | Cholesteryl ester_18:2_[M+NH4]1+ levels | GCST90060220 | 16.54 |
| 490 | Concentration of medium HDL particles (UKB data field 23565) | GCST90269662 | 16.52 |
| 491 | GRSF1 levels | GCST90469407 | 16.51 |
| 492 | Familial combined hyperlipidemia defined by Brunzell criteria | GCST90104003 | 16.51 |
| 493 | Total lipids in medium HDL (UKB data field 23566) | GCST90269663 | 16.48 |
| 494 | ALB levels | GCST90475103 | 16.46 |
| 495 | Phospholipids to total lipids ratio in IDL | GCST90092840 | 16.34 |
| 496 | Docosahexaenoic acid levels | GCST90501984 | 16.34 |
| 497 | Triglycerides in large HDL | GCST90497882 | 16.33 |
| 498 | Alkenylphosphatidylethanolamine (P-20:0/18:2) levels | GCST90025683 | 16.32 |
| 499 | Omega-6 fatty acid levels | GCST90502502 | 16.32 |
| 500 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502388 | 16.31 |
| 501 | ALB levels | GCST90497108 | 16.31 |
| 502 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90501042 | 16.29 |
| 503 | CCL24 levels | GCST90468576 | 16.28 |
| 504 | Treatment or medication use - ezetimibe (UKB data field 20003_1141192736) | GCST90042541 | 16.27 |
| 505 | CDKN1A/DAB2 ratio | GCST90313967 | 16.26 |
| 506 | CA4/FOLR2 ratio | GCST90313585 | 16.25 |
| 507 | Free cholesterol to total lipids ratio in IDL | GCST90092836 | 16.25 |
| 508 | DKK1/PTPN6 ratio | GCST90314478 | 16.24 |
| 509 | Polyunsaturated fatty acid levels | GCST90502134 | 16.23 |
| 510 | Total lipid levels in very large VLDL | GCST90093022 | 16.21 |
| 511 | Phosphatidylcholine_38:5_[M+H]1+/Phosphatidylethanolamine_41:5_[M+H]1+/Phosphatidate_43:6_[M+NH4]1+ levels | GCST90060395 | 16.21 |
| 512 | Total fatty acid levels | GCST90500061 | 16.20 |
| 513 | ALB levels | UKBB00000019 | 16.20 |
| 514 | Total lipids in large VLDL (UKB data field 23496) | GCST90269593 | 16.18 |
| 515 | Triglycerides in LDL | GCST90498472 | 16.16 |
| 516 | CTSB levels | GCST90468908 | 16.13 |
| 517 | HPCAL1/SERPINB9 ratio | GCST90315079 | 16.11 |
| 518 | Phospholipids to total lipids in large LDL percentage (UKB data field 23614) | GCST90269711 | 16.10 |
| 519 | COMP/DPP4 ratio | GCST90314188 | 16.10 |
| 520 | 3-Hydroxybutyrate levels | GCST90092811 | 16.08 |
| 521 | Free Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500398 | 16.05 |
| 522 | HDL cholesterol levels | GCST90497352 | 16.04 |
| 523 | Phospholipid levels in large VLDL | GCST90092876 | 16.04 |
| 524 | DCXR/GSTA1 ratio | GCST90314437 | 16.02 |
| 525 | B3GNT7 levels | GCST90468411 | 16.00 |
| 526 | Membranous nephropathy | GCST010006 | 16.00 |
| 527 | IDP SWI T2star left pallidum | GCST90003869 | 15.99 |
| 528 | CD69/NFATC1 ratio | GCST90313879 | 15.97 |
| 529 | EIF3J levels | GCST90241122 | 15.95 |
| 530 | Superficial cellulitis and abscess (PheCode 681) | GCST90476165 | 15.93 |
| 531 | CD207 levels | GCST90468607 | 15.91 |
| 532 | Triglyceride levels in very large VLDL | GCST90093026 | 15.90 |
| 533 | APOM/MCAM ratio | GCST90313315 | 15.89 |
| 534 | High-density lipoprotein levels (MTAG) | GCST90179147 | 15.88 |
| 535 | Cholesteryl Esters in Medium VLDL | GCST90498939 | 15.88 |
| 536 | Total lipids in very large HDL | GCST90500410 | 15.88 |
| 537 | Cholesterol to Total Lipids in Large HDL percentage | GCST90497730 | 15.87 |
| 538 | Cholesterol to total lipids ratio in medium VLDL | GCST90092917 | 15.84 |
| 539 | PLA2G15/PRCP ratio | GCST90315661 | 15.83 |
| 540 | Concentration of large VLDL particles | GCST90498223 | 15.82 |
| 541 | EREG/GYS1 ratio | GCST90314701 | 15.81 |
| 542 | Cholesteryl Esters to Total Lipids in Small HDL percentage | GCST90499406 | 15.81 |
| 543 | Familial combined hyperlipidemia defined by Dutch criteria | GCST90104005 | 15.81 |
| 544 | Linoleic acid levels | GCST90502012 | 15.79 |
| 545 | MMP9/OSM ratio | GCST90315468 | 15.78 |
| 546 | Cholesterol levels in chylomicrons and extremely large VLDL | GCST90500918 | 15.78 |
| 547 | Reason for reducing amount of alcohol drunk - Health precaution | Alcohol | UKBB00000734 | 15.77 |
| 548 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502373 | 15.76 |
| 549 | FGA levels | GCST90469216 | 15.75 |
| 550 | Phospholipids to Total Lipids in Large VLDL percentage | GCST90498252 | 15.71 |
| 551 | Average diameter for HDL particles | GCST90497454 | 15.70 |
| 552 | Triglycerides in very small VLDL | GCST90500885 | 15.68 |
| 553 | HDL cholesterol levels | GCST90092822 | 15.67 |
| 554 | Phospholipids in very large HDL (UKB data field 23553) | GCST90269650 | 15.65 |
| 555 | Orange juice liking | GCST90094806 | 15.64 |
| 556 | Low hand grip strength (60 years and older) (FNIH) | GCST90007529 | 15.62 |
| 557 | TNFRSF8/TNFRSF9 ratio | GCST90315940 | 15.61 |
| 558 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T375 | ECGA000375 | 15.61 |
| 559 | RNF43 levels | GCST90422482 | 15.61 |
| 560 | X-12411 levels | GCST90200492 | 15.61 |
| 561 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502649 | 15.61 |
| 562 | Omega-6 fatty acid levels | GCST90502514 | 15.58 |
| 563 | Ascites (non malignant) (PheCode 572) | GCST90476090 | 15.58 |
| 564 | Free cholesterol levels in large VLDL | GCST90092872 | 15.58 |
| 565 | Monounsaturated fatty acid levels | GCST90499094 | 15.58 |
| 566 | CD74/TIMD4 ratio | GCST90313896 | 15.53 |
| 567 | Triglyceride levels in VLDL | GCST90093003 | 15.52 |
| 568 | X-24406 metabolite level | GCST90616789 | 15.51 |
| 569 | PLAUR levels | GCST90470251 | 15.48 |
| 570 | Triglycerides to total lipids ratio in medium VLDL | GCST90092927 | 15.47 |
| 571 | Phosphatidylcholine_32:0_[M+H]1+/Phosphatidylethanolamine_35:0_[M+H]1+/Phosphatidate_37:1_[M+NH4]1+ levels | GCST90060270 | 15.46 |
| 572 | ITGB5/VSIR ratio | GCST90315235 | 15.45 |
| 573 | Concentration of large VLDL particles (UKB data field 23495) | GCST90269592 | 15.45 |
| 574 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T376 | ECGA000376 | 15.44 |
| 575 | Triglycerides to total lipids ratio in very small VLDL | GCST90093039 | 15.43 |
| 576 | APOA1 levels | GCST90468331 | 15.43 |
| 577 | Diacylglycerol_36:3_[M+H-H2O]1+ levels | GCST90060189 | 15.42 |
| 578 | DPP4/ITGB1 ratio | GCST90314540 | 15.42 |
| 579 | NCS1/NPY ratio | GCST90315527 | 15.41 |
| 580 | MMP9 levels | GCST90469923 | 15.37 |
| 581 | F-cheese liking (derived food-liking factor) | GCST90094729 | 15.37 |
| 582 | Diacylglycerol_34:2_[M+H-H2O]1+ levels | GCST90060178 | 15.37 |
| 583 | triglyceride (minimum, inv-norm transformed) | GCST90476437 | 15.36 |
| 584 | Triglyceride levels in small LDL | GCST90092966 | 15.34 |
| 585 | Phospholipids to Total Lipids in Very Large HDL percentage | GCST90500474 | 15.33 |
| 586 | Cholesteryl Esters to Total Lipids in Medium LDL percentage | GCST90498747 | 15.31 |
| 587 | Cholesterol in Small LDL | GCST90499555 | 15.30 |
| 588 | Cholesteryl Esters in Large LDL | GCST90497955 | 15.29 |
| 589 | Concentration of very large VLDL particles | GCST90093023 | 15.28 |
| 590 | Omega-6 fatty acids to omega-3 fatty acids ratio | GCST90499194 | 15.27 |
| 591 | CDC37/SNAP29 ratio | GCST90313935 | 15.26 |
| 592 | ADGRE2 levels | GCST90468237 | 15.26 |
| 593 | Pregnenediol disulfate (C21H34O8S2) levels | GCST90199840 | 15.26 |
| 594 | Osteoporosis | musculoskeletal | UKBB00000598 | 15.26 |
| 595 | COLEC12/TNFRSF1A ratio | GCST90314187 | 15.22 |
| 596 | CLEC1B/MGLL ratio | GCST90314097 | 15.22 |
| 597 | Total fatty acid levels | GCST90502722 | 15.22 |
| 598 | PLAU/PLAUR ratio | GCST90315674 | 15.22 |
| 599 | IGSF21 levels | GCST90469538 | 15.21 |
| 600 | Triglycerides in VLDL (UKB data field 23408) | GCST90269505 | 15.20 |
| 601 | Total lipids in very large HDL (UKB data field 23552) | GCST90269649 | 15.18 |
| 602 | Cholesteryl Esters to Total Lipids in Large HDL percentage | GCST90497763 | 15.16 |
| 603 | T1 CAT volume L PlanumPolare | GCST90384086 | 15.15 |
| 604 | Cholesterol in medium HDL (UKB data field 23568) | GCST90269665 | 15.14 |
| 605 | CD300E/EFNA4 ratio | GCST90313797 | 15.14 |
| 606 | Osteoporosis NOS | musculoskeletal | UKBB00000599 | 15.13 |
| 607 | Glycoprotein acetyls levels | GCST90497328 | 15.12 |
| 608 | NPL levels | GCST90470072 | 15.12 |
| 609 | CD84/VASH1 ratio | GCST90313920 | 15.12 |
| 610 | Dysmenorrheic pain severity | GCST006656 | 15.11 |
| 611 | Cholesteryl Esters in HDL | GCST90497368 | 15.10 |
| 612 | CSPG4 levels | GCST90468890 | 15.10 |
| 613 | Gout, strict definition | FING00000588 | 15.09 |
| 614 | Phospholipids in medium HDL (UKB data field 23567) | GCST90269664 | 15.09 |
| 615 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T374 | ECGA000374 | 15.09 |
| 616 | IBD (strict) with PSC | FING00000657 | 15.08 |
| 617 | Phospholipids to total lipids in small LDL percentage (UKB data field 23624) | GCST90269721 | 15.05 |
| 618 | CCL18/TFPI ratio | GCST90313691 | 15.02 |
| 619 | NOMO1 levels | GCST90470060 | 15.02 |
| 620 | Phospholipids to Total Lipids in Medium HDL percentage | GCST90498653 | 15.01 |
| 621 | Cholesterol levels in very small VLDL | GCST90500700 | 14.99 |
| 622 | Cholesteryl Esters to Total Lipids in Very Large HDL percentage | GCST90500359 | 14.98 |
| 623 | Free cholesterol to total lipids ratio in medium HDL | GCST90092897 | 14.96 |
| 624 | DNAJA2/HCLS1 ratio | GCST90314502 | 14.92 |
| 625 | KIAA0040 levels | GCST90422552 | 14.92 |
| 626 | Total Lipids in Medium LDL | GCST90498806 | 14.91 |
| 627 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500692 | 14.90 |
| 628 | Cholesteryl Esters in Medium LDL | GCST90498739 | 14.90 |
| 629 | Phospholipids in HDL | GCST90497437 | 14.89 |
| 630 | rfMRI amplitudes (ICA100 node 15) | GCST90004603 | 14.89 |
| 631 | OLR1/PLAUR ratio | GCST90315584 | 14.89 |
| 632 | Other noninfective gastroenteritis and colitis | FING00001077 | 14.89 |
| 633 | Phospholipids in large VLDL (UKB data field 23497) | GCST90269594 | 14.86 |
| 634 | Abnormality of gait (PheCode 350.2) | GCST90475841 | 14.86 |
| 635 | Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500324 | 14.86 |
| 636 | IDP dMRI TBSS ICVF Cerebral peduncle R | GCST90004341 | 14.81 |
| 637 | Phospholipids in small HDL (UKB data field 23574) | GCST90269671 | 14.79 |
| 638 | Concentration of very large HDL particles (UKB data field 23551) | GCST90269648 | 14.79 |
| 639 | Triglyceride to phosphoglyceride ratio | GCST90499992 | 14.78 |
| 640 | Gestational age at birth (maternal effect) | GCST90268419 | 14.77 |
| 641 | TAX1BP3 levels | GCST90242976 | 14.77 |
| 642 | Free Cholesterol to Total Lipids in Large VLDL percentage | GCST90498204 | 14.77 |
| 643 | Docosahexaenoic acid to total fatty acids percentage | GCST90497268 | 14.75 |
| 644 | ENTPD5 levels | GCST90469121 | 14.75 |
| 645 | CLEC4G/SEMA3F ratio | GCST90314123 | 14.74 |
| 646 | Disorders of skin appendages | FING00000460 | 14.73 |
| 647 | Total lipids in large VLDL | GCST90498216 | 14.73 |
| 648 | Phosphatidylcholine levels | GCST90499240 | 14.71 |
| 649 | Total cholines levels | GCST90497185 | 14.70 |
| 650 | Free cholesterol to total lipids ratio in very small VLDL | GCST90093033 | 14.69 |
| 651 | Sleep duration | Sleep | UKBB00000777 | 14.67 |
| 652 | GOT1 levels | GCST90469379 | 14.67 |
| 653 | Polyunsaturated fatty acid levels | GCST90502140 | 14.66 |
| 654 | Total lipids in very large VLDL (UKB data field 23489) | GCST90269586 | 14.65 |
| 655 | CD4/LILRB4 ratio | GCST90313843 | 14.65 |
| 656 | Omega-3 fatty acid levels | GCST90502055 | 14.63 |
| 657 | ACP5 levels | GCST90468203 | 14.62 |
| 658 | Triglycerides in small HDL | GCST90499516 | 14.62 |
| 659 | Cholesterol esters in very small VLDL | GCST90500740 | 14.62 |
| 660 | Free Cholesterol to Total Lipids in IDL percentage | GCST90497579 | 14.58 |
| 661 | Triglycerides in medium HDL | GCST90498672 | 14.58 |
| 662 | Phospholipids in large VLDL | GCST90498243 | 14.58 |
| 663 | Other specified diseases of sebaceous glands (PheCode 706.8) | GCST90476215 | 14.57 |
| 664 | CRTAM/KLRD1 ratio | GCST90314277 | 14.54 |
| 665 | ALB levels | GCST90497101 | 14.53 |
| 666 | Linoleic acid levels | GCST90498306 | 14.53 |
| 667 | Concentration of very large VLDL particles (UKB data field 23488) | GCST90269585 | 14.52 |
| 668 | Cholesterol levels in very large VLDL | GCST90500518 | 14.51 |
| 669 | Free cholesterol levels in very large VLDL | GCST90093020 | 14.51 |
| 670 | Total lipid levels in medium HDL | GCST90092898 | 14.50 |
| 671 | Phospholipids to total lipids in very small VLDL percentage (UKB data field 23604) | GCST90269701 | 14.47 |
| 672 | Diastolic blood pressure x sex interaction | GCST90335175 | 14.47 |
| 673 | Free cholesterol in large HDL | GCST90497780 | 14.46 |
| 674 | Saturated fatty acids levels | GCST90502186 | 14.45 |
| 675 | Total triglycerides levels | GCST90092992 | 14.45 |
| 676 | Total lipids in very large VLDL | GCST90500614 | 14.44 |
| 677 | Concentration of very small VLDL particles | GCST90500826 | 14.44 |
| 678 | Docosahexaenoic acid to total fatty acids percentage | GCST90502269 | 14.43 |
| 679 | Phospholipids in very small VLDL | GCST90500851 | 14.40 |
| 680 | Gout, unspecified | FING00000589 | 14.40 |
| 681 | Treatment/medication code - omeprazole | Medications | UKBB00000852 | 14.39 |
| 682 | Total triglycerides levels (UKB data field 23407) | GCST90269504 | 14.38 |
| 683 | Triglycerides in very large VLDL (UKB data field 23494) | GCST90269591 | 14.38 |
| 684 | Cholesteryl Esters to Total Lipids in Very Small VLDL percentage | GCST90500754 | 14.38 |
| 685 | Phospholipids in large LDL | GCST90498053 | 14.37 |
| 686 | Concentration of very large VLDL particles | GCST90500631 | 14.36 |
| 687 | Phospholipids to Total Lipids in IDL percentage | GCST90497642 | 14.35 |
| 688 | MMP8 levels | GCST90469922 | 14.34 |
| 689 | CD163/ICAM1 ratio | GCST90313735 | 14.34 |
| 690 | GLB1/IMPA1 ratio | GCST90314932 | 14.33 |
| 691 | Phospholipid levels in very large VLDL | GCST90093024 | 14.30 |
| 692 | IDP dMRI TBSS ICVF Superior cerebellar peduncle R | GCST90004339 | 14.27 |
| 693 | Erysipelas | FING00000518 | 14.26 |
| 694 | Other chronic obstructive pulmonary disease | Chronic lower respiratory diseases | UKBB00000604 | 14.25 |
| 695 | Triglycerides | GCST90018755 | 14.24 |
| 696 | Free cholesterol to total lipids in IDL percentage (UKB data field 23612) | GCST90269709 | 14.24 |
| 697 | Triglycerides in very large HDL | GCST90500482 | 14.23 |
| 698 | Triglycerides to Total Lipids in Small LDL percentage | GCST90499740 | 14.23 |
| 699 | Concentration of medium HDL particles | GCST90092899 | 14.22 |
| 700 | Total lipids in IDL | GCST90497594 | 14.20 |
| 701 | Raw carrot liking | GCST90094818 | 14.20 |
| 702 | AXL/GAS6 ratio | GCST90313419 | 14.19 |
| 703 | ALDH1A1/PKLR ratio | GCST90313245 | 14.18 |
| 704 | Cholesteryl Esters to Total Lipids in IDL percentage | GCST90497549 | 14.16 |
| 705 | Cholesteryl esters in very large HDL (UKB data field 23555) | GCST90269652 | 14.14 |
| 706 | PKD1 levels | GCST90470240 | 14.14 |
| 707 | Total free cholesterol levels | GCST90500063 | 14.14 |
| 708 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502181 | 14.12 |
| 709 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502570 | 14.11 |
| 710 | Phospholipids to Total Lipids in Medium LDL percentage | GCST90498852 | 14.10 |
| 711 | CD300C/MANSC1 ratio | GCST90313791 | 14.09 |
| 712 | Cholesteryl esters in medium HDL (UKB data field 23569) | GCST90269666 | 14.07 |
| 713 | NTRK2 levels | GCST90470097 | 14.06 |
| 714 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502075 | 14.06 |
| 715 | Free cholesterol in large VLDL (UKB data field 23500) | GCST90269597 | 14.03 |
| 716 | DPP4 levels | GCST90469033 | 14.03 |
| 717 | ALB levels | GCST90092807 | 14.03 |
| 718 | FHIT/PARK7 ratio | GCST90314821 | 14.00 |
| 719 | Female infertility, associated with anovulation | FING00000537 | 13.99 |
| 720 | Linoleic acid levels | GCST90502010 | 13.99 |
| 721 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90501031 | 13.97 |
| 722 | Triglyceride levels in HDL | GCST90092829 | 13.95 |
| 723 | Sphingomyelin_32:1_[M+H]1+ levels | GCST90060225 | 13.95 |
| 724 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502068 | 13.94 |
| 725 | Monounsaturated fatty acid levels | GCST90092928 | 13.94 |
| 726 | BTN2A1/LILRB4 ratio | GCST90313546 | 13.93 |
| 727 | Triglyceride levels in small HDL | GCST90092954 | 13.92 |
| 728 | HYOU1/RARRES2 ratio | GCST90315103 | 13.90 |
| 729 | CD74/JAM2 ratio | GCST90313893 | 13.90 |
| 730 | GSTA1 levels | GCST90469411 | 13.88 |
| 731 | CD163/FOLR2 ratio | GCST90313734 | 13.88 |
| 732 | HNMT/SETMAR ratio | GCST90315069 | 13.86 |
| 733 | Cholesteryl esters to total lipids ratio in medium VLDL | GCST90092919 | 13.86 |
| 734 | Nontoxic goitre/thyroid nodule | FING00000887 | 13.85 |
| 735 | Aspartate aminotransferase levels (UKB data field 30650) | GCST90468063 | 13.85 |
| 736 | Saturated fatty acids levels | GCST90502670 | 13.85 |
| 737 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498092 | 13.85 |
| 738 | Cholesterol levels in large VLDL | GCST90092868 | 13.84 |
| 739 | Phospholipids to total lipids ratio in very large HDL | GCST90093013 | 13.83 |
| 740 | Monounsaturated fatty acid levels | GCST90502030 | 13.81 |
| 741 | Concentration of medium LDL particles | GCST90498819 | 13.81 |
| 742 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90499287 | 13.79 |
| 743 | Phospholipids in small LDL | GCST90499681 | 13.79 |
| 744 | ADGRE5 levels | GCST90468238 | 13.78 |
| 745 | ALCAM/MSR1 ratio | GCST90313240 | 13.78 |
| 746 | Osteomyelitis, periostitis, and other infections involving bone (PheCode 710) | GCST90476220 | 13.78 |
| 747 | Concentration of medium HDL particles | GCST90498622 | 13.78 |
| 748 | Degree of unsaturation | GCST90500162 | 13.77 |
| 749 | Cholesterol to total lipids ratio in very small VLDL | GCST90093029 | 13.77 |
| 750 | HCLS1/LAT ratio | GCST90315041 | 13.76 |
| 751 | Apple juice liking | GCST90094690 | 13.75 |
| 752 | Triglycerides to Total Lipids in Small HDL percentage | GCST90499530 | 13.74 |
| 753 | ENPP5 levels | GCST90469116 | 13.74 |
| 754 | Oily fish intake | Diet | UKBB00000547 | 13.74 |
| 755 | Triglyceride levels in medium LDL | GCST90092914 | 13.71 |
| 756 | Cholesterol to Total Lipids in IDL percentage | GCST90497518 | 13.68 |
| 757 | Total fatty acid levels | GCST90502212 | 13.67 |
| 758 | Triglycerides to Total Lipids in Medium VLDL percentage | GCST90499073 | 13.64 |
| 759 | Polyunsaturated fatty acid levels | GCST90092939 | 13.64 |
| 760 | triglyceride (maximum, inv-norm transformed) | GCST90476429 | 13.63 |
| 761 | Triglycerides to Total Lipids in Very Large VLDL percentage | GCST90500695 | 13.63 |
| 762 | Saturated fatty acids levels | GCST90502192 | 13.62 |
| 763 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90500943 | 13.62 |
| 764 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499111 | 13.62 |
| 765 | CDKN1A/FOXO1 ratio | GCST90313970 | 13.61 |
| 766 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499109 | 13.61 |
| 767 | APOE levels | GCST90468338 | 13.61 |
| 768 | Cardiovascular disease | GCST90086057 | 13.60 |
| 769 | LRTM2 levels | GCST90469808 | 13.59 |
| 770 | CCDC80/CCL27 ratio | GCST90313669 | 13.58 |
| 771 | Cake icing liking | GCST90094723 | 13.58 |
| 772 | IDP SWI T2star right pallidum | GCST90003870 | 13.56 |
| 773 | Lysoalkylphosphatidylcholine (O-24:2) levels | GCST90025438 | 13.54 |
| 774 | Triglycerides to Total Lipids in Medium VLDL percentage | GCST90499069 | 13.53 |
| 775 | Phospholipids in small VLDL | GCST90499881 | 13.53 |
| 776 | Free cholesterol to total lipids ratio in very large VLDL | GCST90093021 | 13.52 |
| 777 | APOC1 levels | GCST90468336 | 13.52 |
| 778 | Free Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500598 | 13.50 |
| 779 | Memory loss or impairment | GCST90475544 | 13.49 |
| 780 | Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498919 | 13.49 |
| 781 | Cholesterol levels in very large VLDL | GCST90093016 | 13.49 |
| 782 | Cholesteryl Esters in Small LDL | GCST90499578 | 13.48 |
| 783 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498101 | 13.48 |
| 784 | Free cholesterol to total lipids ratio in medium VLDL | GCST90092921 | 13.48 |
| 785 | CD302/CD99 ratio | GCST90313805 | 13.47 |
| 786 | Cholesterol in Medium LDL | GCST90498707 | 13.47 |
| 787 | Cholesteryl esters in very large VLDL | GCST90500552 | 13.46 |
| 788 | Phospholipid levels in medium HDL | GCST90092900 | 13.45 |
| 789 | DCBLD2/PLA2G15 ratio | GCST90314428 | 13.45 |
| 790 | Omega-3 fatty acids to total fatty acids percentage | GCST90499163 | 13.45 |
| 791 | Medication for pain relief, constipation, heartburn - Laxatives (e.g. Dulcolax, Senokot) | Medication | UKBB00000456 | 13.43 |
| 792 | Phospholipids to Total Lipids in Very Large VLDL percentage | GCST90500665 | 13.43 |
| 793 | Total lipids in small HDL | GCST90499443 | 13.42 |
| 794 | Remnant cholesterol (non-HDL, non-LDL -cholesterol) | GCST90499340 | 13.39 |
| 795 | Free cholesterol to total lipids ratio in large LDL | GCST90092861 | 13.39 |
| 796 | Diacylglycerol_34:1_[M+H-H2O]1+ levels | GCST90060179 | 13.38 |
| 797 | FCAR/LY96 ratio | GCST90314788 | 13.38 |
| 798 | Ratio of triglycerides to phosphoglycerides | GCST90092983 | 13.37 |
| 799 | Saturated fatty acids to total fatty acids percentage | GCST90502207 | 13.35 |
| 800 | Principal component-derived dietary pattern 13 | GCST90133018 | 13.34 |
| 801 | HPCAL1/LAT ratio | GCST90315072 | 13.34 |
| 802 | Cardiorespiratory fitness slope | GCST90093319 | 13.34 |
| 803 | T1 FreeSurfer pial rh lateraloccipital area | GCST90385832 | 13.33 |
| 804 | Obstructive chronic bronchitis | respiratory | UKBB00000546 | 13.33 |
| 805 | RARRES2 levels | GCST90470428 | 13.33 |
| 806 | Cholesteryl ester levels in HDL | GCST90092823 | 13.33 |
| 807 | SNX2 levels | GCST90470701 | 13.33 |
| 808 | Left-hemisphere visual network to accumbens white-matter structural connectivity | GCST90302668 | 13.31 |
| 809 | IFNAR1 levels | GCST90469512 | 13.31 |
| 810 | CHI3L1/PRSS8 ratio | GCST90314044 | 13.30 |
| 811 | HPCAL1/MPIG6B ratio | GCST90315073 | 13.28 |
| 812 | Phospholipids in very large HDL | GCST90500458 | 13.27 |
| 813 | Free cholesterol in small VLDL | GCST90499808 | 13.25 |
| 814 | Triglycerides in VLDL | GCST90500304 | 13.24 |
| 815 | Cholesterol to total lipids in large LDL percentage (UKB data field 23615) | GCST90269712 | 13.24 |
| 816 | Oily fish consumption | GCST90132993 | 13.23 |
| 817 | APOB levels | GCST90497137 | 13.18 |
| 818 | ALB levels | GCST90475100 | 13.18 |
| 819 | DUT levels | GCST90469054 | 13.17 |
| 820 | Triacylglycerol_51:3_[M+NH4]1+ levels | GCST90060494 | 13.17 |
| 821 | NELL2 levels | GCST90470027 | 13.14 |
| 822 | Free cholesterol in very small VLDL | GCST90500774 | 13.14 |
| 823 | Triglycerides in HDL | GCST90497467 | 13.14 |
| 824 | Triglyceride to phosphoglyceride ratio | GCST90499996 | 13.12 |
| 825 | Left-hemisphere default mode network to left-hemisphere default mode network white-matter structural connectivity | GCST90302759 | 13.11 |
| 826 | Total cholesterol minus HDL-C levels | GCST90499129 | 13.11 |
| 827 | Cholesterol in very large HDL (UKB data field 23554) | GCST90269651 | 13.10 |
| 828 | CCL17/THPO ratio | GCST90313689 | 13.10 |
| 829 | LAT2/SERPINB1 ratio | GCST90315279 | 13.10 |
| 830 | Sphingomyelin_34:0_[M+H]1+ levels | GCST90060241 | 13.08 |
| 831 | Triglycerides in IDL | GCST90497661 | 13.07 |
| 832 | Total lipids in large VLDL | GCST90498207 | 13.07 |
| 833 | ALDH1A1/CA3 ratio | GCST90313244 | 13.07 |
| 834 | MMP8/TGFA ratio | GCST90315466 | 13.06 |
| 835 | KIFBP/LYN ratio | GCST90315246 | 13.06 |
| 836 | Cholesteryl Esters to Total Lipids in Small LDL percentage | GCST90499595 | 13.04 |
| 837 | Cholesteryl esters to total lipids ratio in very small VLDL | GCST90093031 | 13.04 |
| 838 | Phosphatidylcholine-O_36:4_[M+H]1+/Phosphatidylcholine-P_36:3_[M+H]1+ levels | GCST90060318 | 13.03 |
| 839 | Cholesterol levels in very large HDL | GCST90500322 | 13.02 |
| 840 | Phospholipids in very small VLDL | GCST90500840 | 13.01 |
| 841 | Polyunsaturated fatty acids levels (UKB data field 23446) | GCST90269543 | 12.99 |
| 842 | ASAH2 levels | GCST90242098 | 12.99 |
| 843 | ALB levels | GCST90269576 | 12.99 |
| 844 | Phosphoglycerides levels | GCST90499259 | 12.99 |
| 845 | IDP T1 FAST ROIs L cerebellum I-IV | GCST90002562 | 12.98 |
| 846 | Omega-3 fatty acids to total fatty acids percentage | GCST90499155 | 12.98 |
| 847 | BTN2A1/SMOC2 ratio | GCST90313549 | 12.97 |
| 848 | Activities undertaken to treat anxiety | Anxiety | UKBB00000009 | 12.97 |
| 849 | LGALS3BP levels | GCST90469760 | 12.96 |
| 850 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502411 | 12.95 |
| 851 | CRKL/MANF ratio | GCST90314269 | 12.95 |
| 852 | Triglycerides to Total Lipids in Small LDL percentage | GCST90499726 | 12.94 |
| 853 | Ratio of monounsaturated fatty acids to total fatty acids | GCST90092929 | 12.94 |
| 854 | Concentration of large LDL particles | GCST90498037 | 12.93 |
| 855 | C2 levels | GCST90468497 | 12.93 |
| 856 | Phospholipids in IDL | GCST90497628 | 12.91 |
| 857 | Prescriptions - losartan | angiotensin receptor blocker,anti-hypertensive,ARB | UKBB00000690 | 12.90 |
| 858 | LRP11/ROR1 ratio | GCST90315330 | 12.88 |
| 859 | CST3/DEFA1_DEFA1B ratio | GCST90314291 | 12.87 |
| 860 | PTPN1/TDRKH ratio | GCST90315745 | 12.87 |
| 861 | Left ventricular end systole anterolateral wall thickness | GCST90278511 | 12.87 |
| 862 | DNAJA2/HPCAL1 ratio | GCST90314503 | 12.87 |
| 863 | Linoleic acid to total fatty acids percentage (UKB data field 23456) | GCST90269553 | 12.87 |
| 864 | Cholesteryl ester_18:1_[M+NH4]1+ levels | GCST90060221 | 12.85 |
| 865 | Cholesteryl Esters in Small HDL | GCST90499386 | 12.85 |
| 866 | Triglycerides to total lipids ratio in very large HDL | GCST90093015 | 12.85 |
| 867 | CDKN1A/PLA2G4A ratio | GCST90313974 | 12.84 |
| 868 | Triglycerides to phosphoglycerides ratio (UKB data field 23435) | GCST90269532 | 12.84 |
| 869 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502069 | 12.82 |
| 870 | CD4 levels | GCST90468636 | 12.82 |
| 871 | Aspartate aminotransferase | Blood biochemistry | UKBB00000052 | 12.81 |
| 872 | HSD17B14 levels | GCST90469483 | 12.81 |
| 873 | CDKN1A/NCK2 ratio | GCST90313973 | 12.79 |
| 874 | C20:4 Lysophosphatidylcholine levels in chronic kidney disease | GCST90257570 | 12.79 |
| 875 | Triglycerides in medium LDL | GCST90498870 | 12.78 |
| 876 | Cholesteryl Esters in Large VLDL | GCST90498154 | 12.77 |
| 877 | CCN2/MGLL ratio | GCST90313714 | 12.76 |
| 878 | Total phospholipids in lipoprotein particles (UKB data field 23411) | GCST90269508 | 12.76 |
| 879 | NRAC levels | GCST90617991 | 12.76 |
| 880 | CXCL17/SFTPA2 ratio | GCST90314341 | 12.76 |
| 881 | Cholesteryl esters to total lipids in medium VLDL percentage (UKB data field 23596) | GCST90269693 | 12.75 |
| 882 | Urine methylsuccinoylcarnitine levels in chronic kidney disease | GCST90265509 | 12.75 |
| 883 | CALCOCO1/TJAP1 ratio | GCST90313611 | 12.73 |
| 884 | Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454) | GCST90269551 | 12.72 |
| 885 | Free Cholesterol to Total Lipids in Small HDL percentage | GCST90499436 | 12.71 |
| 886 | Cholesterol to Total Lipids in Small HDL percentage | GCST90499373 | 12.71 |
| 887 | Medication for pain relief, constipation, heartburn - Ibuprofen (e.g. Nurofen) | Medication | UKBB00000455 | 12.70 |
| 888 | Insomnia (weighted GWA) | GCST90267287 | 12.70 |
| 889 | Diacylglycerol_44:7_[M+H-H2O]1+ levels | GCST90060240 | 12.70 |
| 890 | GLB1 levels | GCST90469355 | 12.69 |
| 891 | Phosphatidylethanolamine (18:0_18:1) levels | GCST90024977 | 12.68 |
| 892 | Cholesteryl ester levels in very large VLDL | GCST90093018 | 12.67 |
| 893 | Total lipid levels in medium VLDL | GCST90092922 | 12.66 |
| 894 | aparc-a2009s rh area G+S-subcentral | GCST90003374 | 12.65 |
| 895 | Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500958 | 12.65 |
| 896 | Omega-6 fatty acids to total fatty acids percentage | GCST90502545 | 12.63 |
| 897 | CLEC4G/NELL2 ratio | GCST90314122 | 12.63 |
| 898 | Free cholesterol in large VLDL | GCST90498185 | 12.62 |
| 899 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T378 | ECGA000378 | 12.62 |
| 900 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T363 | ECGA000363 | 12.62 |
| 901 | Ratio of linoleic acid to total fatty acids | GCST90092881 | 12.62 |
| 902 | Lysoalkylphosphatidylcholine (O-24:1) levels | GCST90024813 | 12.61 |
| 903 | Lysoalkylphosphatidylcholine (O-24:1) levels | GCST90024198 | 12.61 |
| 904 | NAGA levels | GCST90469994 | 12.60 |
| 905 | ASPN levels | GCST90468377 | 12.60 |
| 906 | Cholesterol, total | GCST000760 | 12.58 |
| 907 | OLR1 levels | GCST90470122 | 12.57 |
| 908 | CRADD/STAMBP ratio | GCST90314244 | 12.56 |
| 909 | Total triglycerides levels | GCST90500126 | 12.56 |
| 910 | Phospholipids in very large VLDL (UKB data field 23490) | GCST90269587 | 12.55 |
| 911 | Cholesteryl esters to total lipids ratio in large VLDL | GCST90092871 | 12.55 |
| 912 | Phospholipids to total lipids in large HDL percentage (UKB data field 23634) | GCST90269731 | 12.55 |
| 913 | PLA2G15 levels | GCST90470245 | 12.54 |
| 914 | COL6A3/SMOC2 ratio | GCST90314178 | 12.54 |
| 915 | Principal component-derived dietary pattern 58 | GCST90133061 | 12.54 |
| 916 | Phospholipids in very large VLDL | GCST90500644 | 12.53 |
| 917 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502384 | 12.53 |
| 918 | Monounsaturated fatty acid levels | GCST90502036 | 12.52 |
| 919 | Total lipid levels in lipoprotein particles | GCST90092989 | 12.52 |
| 920 | Cholesterol esters in very large HDL | GCST90500344 | 12.51 |
| 921 | Cholesterol esters in very large HDL | GCST90500354 | 12.51 |
| 922 | S100P levels | GCST90470520 | 12.50 |
| 923 | Cholesteryl Esters to Total Lipids in Very Large VLDL percentage | GCST90500569 | 12.50 |
| 924 | BCAN/MOG ratio | GCST90313480 | 12.49 |
| 925 | RILP/RWDD1 ratio | GCST90315778 | 12.48 |
| 926 | Concentration of LDL particles | GCST90498413 | 12.48 |
| 927 | Omega-6 fatty acid levels | GCST90092933 | 12.47 |
| 928 | Total lipid levels in VLDL | GCST90092999 | 12.45 |
| 929 | MAD1L1 levels | GCST90469836 | 12.44 |
| 930 | Cholesterol to total lipids in medium VLDL percentage (UKB data field 23595) | GCST90269692 | 12.44 |
| 931 | Phospholipids to total lipids ratio in small LDL | GCST90092965 | 12.43 |
| 932 | CD244/TREML2 ratio | GCST90313767 | 12.43 |
| 933 | ESAM/VSIR ratio | GCST90314721 | 12.42 |
| 934 | Concentration of small VLDL particles | GCST90499856 | 12.42 |
| 935 | HAVCR2 levels | GCST90469432 | 12.40 |
| 936 | EIF4G1/HEXIM1 ratio | GCST90314635 | 12.37 |
| 937 | Free cholesterol to total lipids ratio in small VLDL | GCST90092973 | 12.37 |
| 938 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T364 | ECGA000364 | 12.34 |
| 939 | Cholesterol in IDL | GCST90497501 | 12.34 |
| 940 | Free cholesterol in very large HDL | GCST90500380 | 12.32 |
| 941 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502555 | 12.32 |
| 942 | Triglyceride to HDL cholesterol ratio | GCST90295951 | 12.32 |
| 943 | Phospholipids in IDL | GCST90497626 | 12.31 |
| 944 | Alzheimer's disease or family history of Alzheimer's disease | GCST90012877 | 12.30 |
| 945 | ADA2 levels | GCST90468215 | 12.30 |
| 946 | Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501050 | 12.30 |
| 947 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T377 | ECGA000377 | 12.29 |
| 948 | Triglycerides to Total Lipids in IDL percentage | GCST90497682 | 12.29 |
| 949 | SRC/STAT5B ratio | GCST90315882 | 12.28 |
| 950 | Cholesteryl esters to total lipids in small LDL percentage (UKB data field 23626) | GCST90269723 | 12.27 |
| 951 | Triglycerides in small HDL | GCST90499519 | 12.26 |
| 952 | Sphingomyelins levels | GCST90499972 | 12.26 |
| 953 | RHOC/TBCC ratio | GCST90315775 | 12.25 |
| 954 | Total fatty acid levels | GCST90502218 | 12.24 |
| 955 | MANF/PDGFB ratio | GCST90315360 | 12.23 |
| 956 | Phosphatidylcholine-O_40:6_[M+H]1+/Phosphatidylcholine-P_40:5_[M+H]1+ levels | GCST90060420 | 12.22 |
| 957 | Androstenediol (3beta,17beta) disulfate (1) levels | GCST90199842 | 12.21 |
| 958 | Cholesterol in Large VLDL | GCST90498119 | 12.21 |
| 959 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501091 | 12.20 |
| 960 | Phospholipids in large HDL | GCST90497847 | 12.19 |
| 961 | Total lipids in medium HDL | GCST90498604 | 12.18 |
| 962 | Low-density lipoprotein levels (MTAG) | GCST90179148 | 12.17 |
| 963 | BAIAP2 levels | GCST90468419 | 12.17 |
| 964 | BIN2/EREG ratio | GCST90313503 | 12.16 |
| 965 | PON3 levels | GCST90470287 | 12.16 |
| 966 | FXN/TRIAP1 ratio | GCST90314899 | 12.15 |
| 967 | CD84/DKK1 ratio | GCST90313911 | 12.14 |
| 968 | Triglyceride levels in very small VLDL | GCST90132669 | 12.11 |
| 969 | Triacylglycerol_53:2_[M+NH4]1+ levels | GCST90060531 | 12.10 |
| 970 | Total lipids in small VLDL | GCST90499840 | 12.10 |
| 971 | Polyunsaturated fatty acid levels | GCST90502142 | 12.09 |
| 972 | Free cholesterol in large LDL | GCST90497981 | 12.08 |
| 973 | SERPINF2 levels | GCST90470599 | 12.08 |
| 974 | CTSS levels | GCST90468916 | 12.07 |
| 975 | Cholesteryl Esters in LDL | GCST90498374 | 12.06 |
| 976 | Omega-6 fatty acid levels | GCST90502095 | 12.06 |
| 977 | Cholesterol to total lipids ratio in very large VLDL | GCST90093017 | 12.05 |
| 978 | ANGPTL2 levels | GCST90468303 | 12.04 |
| 979 | Modified Stumvoll Insulin Sensitivity Index | GCST90267574 | 12.03 |
| 980 | CCL18/RARRES2 ratio | GCST90313690 | 12.02 |
| 981 | CDKN1A/TMSB10 ratio | GCST90313978 | 12.01 |
| 982 | CASP3/CRKL ratio | GCST90313631 | 12.01 |
| 983 | Total Alkenylphosphatidylcholine levels | GCST90025835 | 12.00 |
| 984 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90093042 | 11.99 |
| 985 | HGF/MMP9 ratio | GCST90315056 | 11.98 |
| 986 | Triglycerides to Total Lipids in Small VLDL percentage | GCST90499934 | 11.98 |
| 987 | Triglycerides in very large HDL | GCST90500481 | 11.98 |
| 988 | VSTM2B levels | GCST90471056 | 11.97 |
| 989 | Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500539 | 11.97 |
| 990 | Triglycerides in large HDL | GCST90497888 | 11.97 |
| 991 | CCL5/LAMA4 ratio | GCST90313703 | 11.96 |
| 992 | Omega-3 fatty acid levels | GCST90502425 | 11.95 |
| 993 | Docosahexaenoic acid levels | GCST90501978 | 11.95 |
| 994 | C-reactive protein | Blood biochemistry | UKBB00000113 | 11.95 |
| 995 | Free cholesterol in very large VLDL (UKB data field 23493) | GCST90269590 | 11.94 |
| 996 | FBP1 levels | GCST90469195 | 11.91 |
| 997 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502633 | 11.91 |
| 998 | FUT8/VEGFC ratio | GCST90314896 | 11.91 |
| 999 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500920 | 11.90 |
| 1000 | MMP1/SERPINB6 ratio | GCST90315462 | 11.89 |